BTIG analyst Mark Massaro maintained a Buy rating on Exact Sciences (EXAS – Research Report) yesterday and set a price target of $65.00. The ...

Scotiabank raised the firm’s price target on Exact Sciences (EXAS) to $73 from $70 and keeps an Outperform rating on the shares. Exact’s Q4 was ...

Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conferences and invited ...

CIBC Asset Management Inc raised its holdings in Exact Sciences Co. (NASDAQ:EXAS – Free Report) by 14.0% in the fourth ...

Rhumbline Advisers lowered its holdings in shares of Exact Sciences Co. (NASDAQ:EXAS – Free Report) by 2.7% during the fourth ...

Exact Sciences posted strong Q4 revenue growth but faced a significant EPS miss. Find out why I remain bullish on EXAS stock.

Exact Sciences has a multipronged approach to cancer testing. Current products are Cologuard, its flagship stool-based screening test for colorectal cancer, or CRC, and Oncotype DX, its tissue-based ...

What Happened? Shares of diagnostic company Exact Sciences Corporation (NASDAQ:EXAS) fell 5.9% in the morning session after the company reported underwhelming fourth-quarter 2024 results as profit ...

Two employers sued over the health law mandate that requires preventive care coverage but a testing firm CEO think other ...

The latest quarterly earnings call from Exact Sciences has revealed a remarkable performance, solidifying its position as a ...

The company best known for its Cologuard colon cancer screening test posted a loss of $864.6 million, or $4.67 per share, on ...

Operator Good day, everyone, and welcome to the Exact Sciences fourth quarter 2024 earnings call. Today's call is being ...